# Nuclide record radionuclide-parp-combination (technology). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/technologies/radionuclide-parp-combination/>
  a schema:MedicalTherapy ;
  nuclide:kind "technology" ;
  schema:identifier "radionuclide-parp-combination" ;
  schema:name "Radioligand plus DNA-repair inhibitor combinations"@en ;
  schema:description "Adding a PARP or ATR inhibitor to a radioactive drug so the tumour cannot repair the damage the radiation causes."@en ;
  schema:url <https://nuclide.cc/technologies/radionuclide-parp-combination/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?term=lutetium%20PSMA%20olaparib> ;
  nuclide:status "phase-1" ;
  nuclide:tag "frontier", "promising" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/neuroendocrine/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/parp/>, <https://nuclide.cc/targets/psma/>, <https://nuclide.cc/targets/sstr2/> .